Head and neck cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 69
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• VEGF 4
• MYC 0
• YAP 1
• MET 3
• CLDN18 0
• HIF-1 0
• IL-6 2
• JNK 0
• AMPK 0
• PARP 1
• FGFR 1
• B7-H3 5
• COX-2 0
• GPX4 0
• LAG-3 2
• TROP2 5
• EZH2 0
• MEK 0
• CD47 1
• METTL3 0
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CXCR4 0
• HER3 4

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,127 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

  NCT01810913· National Cancer Institute (NCI)· Updated 2 Nov 2026

  “Other - Assessing accrual feasibility”Registry text, quoted unchanged. Source

• Terminated

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· Merus B.V.· Updated 26 Oct 2026

  “The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-risk concern with petosemtamab. Ongoing participants will have access to treatment outside of this trial.”Registry text, quoted unchanged. Source

• Terminated

  A Study of E7130 in Participants With Solid Tumors

  NCT03444701· Eisai Co., Ltd.· Updated 23 Oct 2026

  “The trial was prematurely terminated due to the sponsor's decision.”Registry text, quoted unchanged. Source

• Withdrawn

  Digital Phenotyping of Psychological Distress in Skin Cancer Patients

  NCT07670403· West China Hospital· Updated 16 Oct 2026

  “poor accrual”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

  NCT06741982· West China Hospital· Updated 16 Oct 2026

  “The study was withdrawn prior to participant enrollment due to administrative and protocol optimization considerations.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6

  NCT06091930· Boehringer Ingelheim· Updated 14 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

  NCT03881488· Compass Therapeutics· Updated 9 Oct 2026

  “The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm was terminated. The monotherapy arm of the study was fully enrolled and completed.”Registry text, quoted unchanged. Source

• Withdrawn

  Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

  NCT07513324· Dana-Farber Cancer Institute· Updated 8 Oct 2026

  “study halted prematurely prior to enrollment of first participant”Registry text, quoted unchanged. Source

• Terminated

  Mental Health App for Cancer Survivors Study

  NCT06472726· University of Wisconsin, Madison· Updated 2 Oct 2026

  “App developer is no longer in business”Registry text, quoted unchanged. Source

• Terminated

  A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

  NCT04844073· Takeda· Updated 24 Sept 2026

  “Sponsor decision based on limited anti-cancer activity of TAK-186.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

  NCT07667400· National Cancer Institute (NCI)· Source

• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

  NCT06589804· National Cancer Institute (NCI)· Source

• A Study of Neurocognitive Tests and Questionnaires for People With Head and Neck Cancer Who Are Undergoing Radiation Therapy

  NCT05207098· Memorial Sloan Kettering Cancer Center· Source

• Effectiveness of Phenotype-based Pain Management Guidelines for Head and Neck Cancer Related Pain: a Pilot Study

  NCT07919444· Shaukat Khanum Memorial Cancer Hospital & Research Centre· Source

• Phenotype-based Model for Managing Chronic Post-treatment Pain Among Head and Neck Cancer Survivors: a Pilot Study

  NCT07919457· Shaukat Khanum Memorial Cancer Hospital & Research Centre· Source

• Feasibility of Cough Skill Training in Individuals With Head and Neck Cancer

  NCT07756684· Boston University Charles River Campus· Source

• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

  NCT05063552· National Cancer Institute (NCI)· Source

• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

  NCT06385080· Janssen Research & Development, LLC· Source

• A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07219212· Johnson & Johnson Enterprise Innovation Inc.· Source

• BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

  NCT05136196· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 241
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 6
• Exome Sequencing 22
• Proteomics 64
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 330
• Liquid Biopsy 33
• Circulating Tumor DNA 56
• Xenograft Model Antitumor Assays 305
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 272
• Machine Learning 232
• Deep Learning 186
• Cohort Studies 294
• Genome-Wide Association Study 55

• Health-related quality of life as a complementary prognostic marker in nasopharyngeal carcinoma: an explainable machine-learning survival analysis.

  Qual Life Res, Nov 2026

• AI-driven infrared spectroscopy in salivary oral leukoplakia.

  Clin Oral Investig, Nov 2026

• Explainable computational framework for subtype classification and biomarker identification in head and neck squamous cell carcinoma using machine learning.

  PLoS One, Nov 2026

• Early vs late fusion of qMIDS with machine learning based classifiers for oral cancer diagnosis from gene expression data.

  PLoS Comput Biol, Oct 2026

• Incorporating natural language processing-derived features from pathology reports into machine learning models to predict differentiated thyroid cancer recurrence.

  Front Endocrinol (Lausanne), Oct 2026

• Network pharmacology and machine learning reveal kit as a target of roburic acid in anaplastic thyroid carcinoma: Preliminary in vitro validation.

  PLoS One, Oct 2026

• Detection of Cervical Nodal Metastasis in Oral Squamous Cell Carcinoma Using Elastic Scattering Spectroscopy: Ex Vivo Diagnostic Modeling Study.

  JMIR Cancer, Oct 2026

• Effectiveness of radiotherapy or chemoradiotherapy in older patients with advanced-stage, non-surgically treated head and neck cancer: A machine learning analysis.

  Med Oncol, Oct 2026

• A genetic algorithm-optimized EWMA control chart integrating machine learning-based risk prediction for multistage thyroid cancer treatment monitoring.

  PLoS One, Oct 2026

• An explainable and leakage-aware machine learning model for early risk stratification of radioiodine-refractory differentiated thyroid cancer: development and single-center geographic external validation.

  Front Endocrinol (Lausanne), Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.